LABD — Direxion Daily S&P Biotech Bear 3x Shares ETF
LABD seeks -3x the daily return of the S&P Biotech Select Industry Index, rising when biotech stocks decline. It is the inverse counterpart to LABU. WARNING: Given biotech's extreme inherent volatility, LABD experiences among the most severe volatility decay of any inverse ETF. LABD is designed for very short-term bearish biotech positions, often around specific FDA rejection events or sector-wide risk-off rotation. Not for buy-and-hold under any circumstances.
Top Holdings
Strategy
- →SHORT-TERM BEARISH BIOTECH TRADING ONLY — extreme decay in volatile biotech sector
- →Use for specific bearish biotech thesis around anticipated FDA rejections or sector rotation
- →Exit immediately after a biotech sector decline materializes
- →Consider put options on XBI as an alternative with defined maximum loss
Best For
- ✓Very short-term bearish traders with specific conviction on biotech sector decline
- ✓Those hedging biotech long positions temporarily around specific risk events
- ✓Sophisticated traders who follow FDA catalysts and short biotech around adverse outcomes
- ✓Active sector traders with defined exit strategies
Key Risks
- ⚠EXTREME RISK AND DECAY — biotech volatility makes inverse ETF decay especially severe
- ⚠Highest expense ratio in the leveraged/inverse group at 1.04%
- ⚠A positive FDA announcement can cause LABD to lose 30–50% in a single day
- ⚠NOT for any extended holding period
Similar ETFs
Frequently Asked Questions
Can both LABU and LABD lose money?
Yes. Due to volatility decay, both LABU and LABD can lose significant value during volatile sideways biotech market periods, even if the sector ends up roughly flat. This is the mathematical reality of daily leveraged ETF rebalancing. This is educational content, not financial advice.
Is LABD a good hedge during a biotech bear market?
LABD can profit during a sustained biotech decline, but the extreme decay means you must time the entry and exit very carefully. A tactical hedge using put options on XBI may provide more defined risk. This is educational content, not financial advice.
What is LABD's expense ratio?
LABD charges 1.04% annually — the highest in this group. Combined with biotech volatility decay and leverage costs, LABD is expensive to hold. This is educational content, not financial advice.
When might LABD be used tactically?
LABD might be used for a few hours to days around an anticipated negative FDA announcement, a clinical trial failure, or a broader biotech sector sell-off. Holding beyond the immediate event creates severe decay risk. This is educational content, not financial advice.
Is LABD riskier than SQQQ?
LABD tracks biotech — one of the most volatile equity sectors — at -3x leverage. SQQQ tracks the NASDAQ-100 — a large-cap tech index — at -3x. LABD has higher single-day move potential due to binary biotech events, making it arguably more dangerous for any given position. This is educational content, not financial advice.
Recommended Resources
Tools & books I actually use and recommend
Interactive Brokers
Low commissions, global market access, and professional-grade tools. This is where I hold my positions.
Open an AccountA Random Walk Down Wall Street
Burton Malkiel's classic case for index investing. The book that convinced millions to stop stock-picking.
View on AmazonTradingView
Best charting platform out there. Real-time data, screeners, and a community of millions of traders.
Try TradingViewSome links above are affiliate links. I only recommend products I personally use. See my full disclosures.